Melanoma vax trumps rival therapies

About 50 patients in South Australia with inoperable and advanced melanoma initially received single doses of the vaccine twice a week for six months as part of a clinical trial. 

Patients then received the vaccine monthly for six months, and on stabilisation or complete response, received it once every three months thereafter. The trial has been running for 10 years. 

Remarkably, 15% survived for more than five years despite having stage III or stage IV cancer.

Nearly 30% survived to 23 months or longer, and a clinically meaningful response was observed in close to 78% of patients.